Heterogeneity in Lung 18FDG Uptake in Pulmonary Arterial Hypertension: Potential of Dynamic 18FDG Positron Emission Tomography With Kinetic Analysis as a Bridging Biomarker for Pulmonary Vascular Remodeling Targeted Treatments

• Published in: Circulation (New York, N.Y.) N.Y.), 2013-09, Vol.128 (11), p.1214-1224
• Main Authors: Zhao, Lan, Ashek, Ali, Wang, Lei, Fang, Wei, Dabral, Swati, Dubois, Olivier, Cupitt, John, Pullamsetti, Soni Savai, Cotroneo, Emanuele, Jones, Hazel, Tomasi, Gianpaolo, Nguyen, Quang-De, Aboagye, Eric O., El-Bahrawy, Mona A., Barnes, Gareth, Howard, Luke S., Gibbs, J. Simon R., Gsell, Willy, He, Jian-Guo, Wilkins, Martin R.
• Format: Article
• Language: English
• Subjects: Arterial hypertension. Arterial hypotension; Biological and medical sciences; Blood and lymphatic vessels; Cardiology. Vascular system; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Medical sciences; Pneumology; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/CIRCULATIONAHA.113.004136

BACKGROUND—Pulmonary arterial hypertension (PAH) is a disease of progressive vascular remodeling, characterized by dysregulated growth of pulmonary vascular cells and inflammation. A prevailing view is that abnormal cellular metabolism, notably aerobic glycolysis that increases glucose demand, underlies the pathogenesis of PAH. Increased lung glucose uptake has been reported in animal models. Few data exist from patients with PAH. METHODS AND RESULTS—Dynamic positron emission tomography imaging with fluorine-18–labeled 2-fluoro-2-deoxyglucose (FDG) ligand with kinetic analysis demonstrated increased mean lung parenchymal uptake in 20 patients with PAH, 18 with idiopathic PAH (IPAH) (FDG score3.27±1.22), and 2 patients with connective tissue disease (5.07 and 7.11) compared with controls (2.02±0.71; P